KFAR SAVA, Israel, October 20, 2022–(BUSINESS WIRE)–MediCane Health Inc. (along with its subsidiaries together referred to as “MediCane”) today announced the recruitment of the first patient for its clinical study designed to achieve relief of agitation and disruptive behaviors in subjects with probable Alzheimer’s disease (AD) who do not respond or only partially respond to treatment with antipsychotic medications.
Berlin-based Sanity Group has signed new, exclusive supply agreements for medical cannabis with partners from Portugal, South Africa and Canada, securing further exclusive rights to around 20 high-THC cannabis flos from selected cultivars with a minimum volume of three tons per year for the brands Vayamed and AVAAY Medical. Deliveries are already scheduled to start at the end of the third quarter and beginning of the fourth quarter of 2022. In addition, further important strategic partnerships have been signed.
As part of a collaboration between Dr. Reddy’s and MediCane that started in 2021, MediCane will supply
the medical cannabis products to Dr. Reddy’s from its
EU-GMP-certified facilities in Portugal along with providing logistical and regulatory support. As the exclusive distributor of the products in Germany, Dr. Reddy’s will provide access to MediCane’s medical cannabis products supported by a specialized field force that can provide education on the use of the products and guidance on the health insurance reimbursement process to healthcare professionals. The launch marks MediCane’s entry into the pharmaceutical sector of a major European market.
MediCane Health Inc. announces that its Portuguese subsidiary MHI Cultivo Medicinal has received European Union Good Manufacturing Practices (EU-GMP) certification from Infarmed, the Portuguese National Authority for Medicines and Health products, to produce cannabis for medical and research purposes. MediCane .
is the third cannabis company in Portugal to be granted EU-GMP certification. The certification provides MediCane with the ability to manufacture and export cannabis-based preparations, extracts, and substances for medical.
and research use in permitted jurisdictions throughout
the European Union, making it well-positioned to be
a cannabis export hub to Europe.
MediCane Health Inc. is pleased to announce the awarding of an IMC-GMP license for its new manufacturing facility in Kfar Saba, Israel. The approval received this month will enable MediCane to manufacture dry herb and cannabis-based oils, as well as to produce novel formulations for its in-house R&D activity.